A method of immunoassay for detecting and/or monitoring a cardiovascular disease in a patient and/or assessing the likelihood of or the severity of a cardiovascular disease in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the α3 chain of type VI collagen, and/or contacting a biofluid sample from the patient with a monoclonal antibody that specifically binds to a C-terminal neo-epitope of the N-terminal propeptide of type III collagen.

Provided herein are ionic self-assembling peptides, pharmaceutical compositions comprising the peptides, and methods of using and making the same.

Disclosed herein are compositions and methods for their use in treating dental disorders, whitening teeth, restoring and retaining the tooth structure and restoring the mineral content of the tooth-mineral loss due to demineralization, wherein the compositions include a first formulation that includes a polypeptide effective to treat a dental disorder and/or whiten teeth, and one or more further formulations including at least one calcium ion source and/or at least one phosphate ion source, wherein the first formulation is configured to release the polypeptide more rapidly than Ca.sup.2+ is released from the at least one calcium ion source and PO.sub.4.sup.3− is released from the at least one phosphate ion source.

Described are compositions and methods for cartilage replacement. Also described are collagen scaffolds comprising the composition described herein.

Described are compositions and methods for cartilage replacement. Also described are collagen scaffolds comprising the composition described herein.

A peptide composition comprises a collagen peptide, and at least three first compounds selected from the group consisting of isovaleric aldehyde, 1-octen-3-ol, phenylacetaldehyde and methional.

Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, and methods of preparing the conjugates.

Disclosed herein are conjugates including a fatty acid, a self-assembly domain, and a polypeptide, where the conjugates have phase transition behavior. Further disclosed are methods of using the conjugates to treat disease, methods of delivering an agent, and methods of preparing the conjugates.

The present invention relates to a method for controlling differentiation of pluripotent stem cells, which method comprises selecting a laminin or a fragment thereof based on binding affinity for the pluripotent stem cells and inducing differentiation of the pluripotent stem cells in the presence of the laminin or a fragment thereof. Here, the binding affinity for cells can be assessed by time-course observation of the survival rate and motility of the cells. According to the present invention, a cell population containing any desired proportion of differentiated cells can be produced from pluripotent stem cells in a simple manner. The cell population obtained by this production method is very useful for cell therapy-based treatment strategies for diseases.

An object of the invention is to provide a method for producing a mesenchymal stem cell in which differentiation into an adipocyte is suppressed with a simple step, a mesenchymal stem cell, a method for producing a differentiation-induced cell using the method for producing a mesenchymal stem cell described above, a differentiation-induced cell, and an inhibitor of differentiation into an adipocyte. According to the invention, there is provided a method for producing a mesenchymal stem cell, including: a step of culturing a mesenchymal stem cell in a liquid medium in which a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen has been dissolved, wherein differentiation into an adipocyte is suppressed.